EndoscopIc Sleeve Gastroplasty Efficacy (ENvISaGE) Study: Characteristics of ESG and matched LSG patients from the first Queensland ESG clinic

Skye Marshall; Felicity  Cohen; Graeme Rich; Asha Soni; Elisabeth Isenring

doi:10.1007/s11695-019-04101-1

Abstract

Background: The endoscopic sleeve gastroplasty (ESG), new to Australia, is a minimally invasive procedure designed to mimic some of the effects of the laparoscopic sleeve gastroplasty (LSG). The prospective observational ENvISaGE study follows ESG and matched LSG patients of the first ESG clinic in Queensland, Australia, to determine the procedural safety, change in body composition, comorbidity risk factors, and quality of life in obese adults.
Objectives: To report the baseline characteristics of patients recruited to the ENvISaGE study.
Methods: Body composition was measured by DXA, quality of life by Impact of weight on Quality of Life Assessment Tool, gastrointestinal symptoms by Gastrointestinal Symptom Rating Scale. Blood pressure, lipid profile, liver enzymes, and glycaemia was also measured. Adverse events were recorded.
Results: 12 LSG patients were matched for age, gender, and BMI against 12 ESG patients recruited in the first 6-months (mean 41.3 years, 75% female, mean BMI 37.3kg/m2). Both cohorts had substantially higher gastrointestinal symptoms and worse weight-related quality of life than population norms. LSG patients had higher HbA1c (34.0 vs 27.3mmol/mol; p=0.025), back or joint pain (6 vs 2 patients; p=0.058), and worse weight-related sexual life (12.9 vs 9.7 score; p=0.070) than ESG patients at baseline. No serious adverse events were recorded. One ESG participant had a suspected mild allergic skin reaction to routine post-procedure antibiotics.
Conclusion: The ESG appears safe for the treatment of obesity. Patients electing the ESG have similar characteristics as patients electing to undergo the LSG; however, may have fewer comorbidities.

Original language	English
Article number	PO-161
Pages (from-to)	564
Journal	Obesity Surgery
Volume	29
Issue number	S5
DOIs	https://doi.org/10.1007/s11695-019-04101-1
Publication status	Published - Sep 2019
Event	24th International Federation for the Surgery of Obesity and Metabolic Disorders World Congress - Madrid, Spain Duration: 3 Sep 2019 → 7 Sep 2019 Conference number: 24th https://www.ifso2019.com/

Access to Document

10.1007/s11695-019-04101-1

Poster Presentation - EndoscopIc Sleeve Gastroplasty Efficacy (ENvISaGE) StudyAccepted author manuscript, 1.19 MBLicence: CC BY-NC-ND

Fingerprint Dive into the research topics of 'EndoscopIc Sleeve Gastroplasty Efficacy (ENvISaGE) Study: Characteristics of ESG and matched LSG patients from the first Queensland ESG clinic'. Together they form a unique fingerprint.

Projects

2 Active

Nutrition to optimise surgical outcomes

Marshall, S., Reidlinger, D., O'Neill, H., Isenring, E. & Van der Meij, B.

1/01/18 → 30/06/26

Project: Research

Bond University Nutrition and Dietetics Research Group Research Collaborations with External Clinical Partners

Marshall, S., Isenring, E., MacKenzie-Shalders, K., Kelly, J., Campbell, K., Van der Meij, B., Cox, G., Reidlinger, D., Mayr, H., Banbury, M., Nucera, R., Jenkins, J., McCray, S., Canavan, R., Parker, B., de Groot, L., Cohen, F., Rich, G., Soni, A., McCarthy, A. L., Mackay, H., Young, A. M., Hickman, I., Wilkinson, S. A., Kiss, N. & Ali, A.

1/01/14 → …

Project: Research

Cite this

Marshall, S., Cohen, F., Rich, G., Soni, A., & Isenring, E. (2019). EndoscopIc Sleeve Gastroplasty Efficacy (ENvISaGE) Study: Characteristics of ESG and matched LSG patients from the first Queensland ESG clinic. Obesity Surgery, 29(S5), 564. [PO-161]. https://doi.org/10.1007/s11695-019-04101-1

@article{b44298b44e154c0fa7480b5cc3a92a10,

title = "EndoscopIc Sleeve Gastroplasty Efficacy (ENvISaGE) Study: Characteristics of ESG and matched LSG patients from the first Queensland ESG clinic",

abstract = "Background: The endoscopic sleeve gastroplasty (ESG), new to Australia, is a minimally invasive procedure designed to mimic some of the effects of the laparoscopic sleeve gastroplasty (LSG). The prospective observational ENvISaGE study follows ESG and matched LSG patients of the first ESG clinic in Queensland, Australia, to determine the procedural safety, change in body composition, comorbidity risk factors, and quality of life in obese adults.Objectives: To report the baseline characteristics of patients recruited to the ENvISaGE study. Methods: Body composition was measured by DXA, quality of life by Impact of weight on Quality of Life Assessment Tool, gastrointestinal symptoms by Gastrointestinal Symptom Rating Scale. Blood pressure, lipid profile, liver enzymes, and glycaemia was also measured. Adverse events were recorded.Results: 12 LSG patients were matched for age, gender, and BMI against 12 ESG patients recruited in the first 6-months (mean 41.3 years, 75{\%} female, mean BMI 37.3kg/m2). Both cohorts had substantially higher gastrointestinal symptoms and worse weight-related quality of life than population norms. LSG patients had higher HbA1c (34.0 vs 27.3mmol/mol; p=0.025), back or joint pain (6 vs 2 patients; p=0.058), and worse weight-related sexual life (12.9 vs 9.7 score; p=0.070) than ESG patients at baseline. No serious adverse events were recorded. One ESG participant had a suspected mild allergic skin reaction to routine post-procedure antibiotics.Conclusion: The ESG appears safe for the treatment of obesity. Patients electing the ESG have similar characteristics as patients electing to undergo the LSG; however, may have fewer comorbidities.",

author = "Skye Marshall and Felicity Cohen and Graeme Rich and Asha Soni and Elisabeth Isenring",

note = "Submitted. Awaiting outcome.",

year = "2019",

month = "9",

doi = "10.1007/s11695-019-04101-1",

language = "English",

volume = "29",

pages = "564",

journal = "Obesity Surgery",

issn = "0960-8923",

publisher = "Springer",

number = "S5",

}

EndoscopIc Sleeve Gastroplasty Efficacy (ENvISaGE) Study: Characteristics of ESG and matched LSG patients from the first Queensland ESG clinic. / Marshall, Skye; Cohen, Felicity ; Rich, Graeme; Soni, Asha; Isenring, Elisabeth.

In: Obesity Surgery, Vol. 29, No. S5, PO-161, 09.2019, p. 564.

Research output: Contribution to journal › Meeting Abstract › Research › peer-review

TY - JOUR

T1 - EndoscopIc Sleeve Gastroplasty Efficacy (ENvISaGE) Study: Characteristics of ESG and matched LSG patients from the first Queensland ESG clinic

AU - Marshall, Skye

AU - Cohen, Felicity

AU - Rich, Graeme

AU - Soni, Asha

AU - Isenring, Elisabeth

N1 - Submitted. Awaiting outcome.

PY - 2019/9

Y1 - 2019/9

N2 - Background: The endoscopic sleeve gastroplasty (ESG), new to Australia, is a minimally invasive procedure designed to mimic some of the effects of the laparoscopic sleeve gastroplasty (LSG). The prospective observational ENvISaGE study follows ESG and matched LSG patients of the first ESG clinic in Queensland, Australia, to determine the procedural safety, change in body composition, comorbidity risk factors, and quality of life in obese adults.Objectives: To report the baseline characteristics of patients recruited to the ENvISaGE study. Methods: Body composition was measured by DXA, quality of life by Impact of weight on Quality of Life Assessment Tool, gastrointestinal symptoms by Gastrointestinal Symptom Rating Scale. Blood pressure, lipid profile, liver enzymes, and glycaemia was also measured. Adverse events were recorded.Results: 12 LSG patients were matched for age, gender, and BMI against 12 ESG patients recruited in the first 6-months (mean 41.3 years, 75% female, mean BMI 37.3kg/m2). Both cohorts had substantially higher gastrointestinal symptoms and worse weight-related quality of life than population norms. LSG patients had higher HbA1c (34.0 vs 27.3mmol/mol; p=0.025), back or joint pain (6 vs 2 patients; p=0.058), and worse weight-related sexual life (12.9 vs 9.7 score; p=0.070) than ESG patients at baseline. No serious adverse events were recorded. One ESG participant had a suspected mild allergic skin reaction to routine post-procedure antibiotics.Conclusion: The ESG appears safe for the treatment of obesity. Patients electing the ESG have similar characteristics as patients electing to undergo the LSG; however, may have fewer comorbidities.

AB - Background: The endoscopic sleeve gastroplasty (ESG), new to Australia, is a minimally invasive procedure designed to mimic some of the effects of the laparoscopic sleeve gastroplasty (LSG). The prospective observational ENvISaGE study follows ESG and matched LSG patients of the first ESG clinic in Queensland, Australia, to determine the procedural safety, change in body composition, comorbidity risk factors, and quality of life in obese adults.Objectives: To report the baseline characteristics of patients recruited to the ENvISaGE study. Methods: Body composition was measured by DXA, quality of life by Impact of weight on Quality of Life Assessment Tool, gastrointestinal symptoms by Gastrointestinal Symptom Rating Scale. Blood pressure, lipid profile, liver enzymes, and glycaemia was also measured. Adverse events were recorded.Results: 12 LSG patients were matched for age, gender, and BMI against 12 ESG patients recruited in the first 6-months (mean 41.3 years, 75% female, mean BMI 37.3kg/m2). Both cohorts had substantially higher gastrointestinal symptoms and worse weight-related quality of life than population norms. LSG patients had higher HbA1c (34.0 vs 27.3mmol/mol; p=0.025), back or joint pain (6 vs 2 patients; p=0.058), and worse weight-related sexual life (12.9 vs 9.7 score; p=0.070) than ESG patients at baseline. No serious adverse events were recorded. One ESG participant had a suspected mild allergic skin reaction to routine post-procedure antibiotics.Conclusion: The ESG appears safe for the treatment of obesity. Patients electing the ESG have similar characteristics as patients electing to undergo the LSG; however, may have fewer comorbidities.

U2 - 10.1007/s11695-019-04101-1

DO - 10.1007/s11695-019-04101-1

M3 - Meeting Abstract

VL - 29

SP - 564

JO - Obesity Surgery

JF - Obesity Surgery

SN - 0960-8923

IS - S5

M1 - PO-161

ER -